Usefulness of preoperative chemoradiation in locally advanced XXXX .

@entity1 @entity137 @entity417 @entity882 @entity66 @entity957 @entity900 @entity2622 @entity189 @entity260 @entity1398 @entity3847 @entity420 @entity1487
This study investigated response rate, @entity137 , and influence on intra- and postoperative complications of neoadjuvant concurrent chemoradiation in locally advanced (Figo @entity3847 ) cervical @entity189 . Twenty-eight @entity1 (median age 46.5 years, age range 29-73 years), diagnosed as having @entity957 (n=21), @entity420 (n=6), and undifferentiated @entity189 (n=1), entered this study. The chemoradiation protocol included external radiotherapy to the pelvis (39.6 Gy), intra-arterial or intravenous infusion of @entity900 (70 mg/m2 on days 1 and 22), and 24-hour continuous intravenous infusion of @entity1487 (700 mg/m2 on days 1-4 and 22-25). Two weeks after the end of chemoradiotherapy, the @entity1 underwent restaging followed by suitable operation including pelvic lymphadenectomy. The median follow-up period in the surviving @entity1 was 13.1 months. The response rate for chemoradiation was 93% (26/28). The 2-year disease free survival was 85.2%. Grade 3-4 @entity1398 was observed in 14 @entity1 (50%), 4 @entity1 (14%) showed grade 3 @entity417 , and 5 @entity1 (17.8%) showed grade 3-4 @entity882 . Nineteen @entity1 (67.8%) could undergo surgery after concurrent chemoradiation. Pathological examination revealed a complete response (pT0) in 7 @entity1 , and 5 @entity1 showed only microscopic @entity66 (pTmic). In 4 @entity1 , there were intraoperative complications: vesical lesions in 2 (10%) and small intestine lesions in 2 (10%). Neoadjuvant therapy with concurrent chemoradiation for locally advanced @entity2622 is effective, safe, and useful for increasing operability rates as well as @entity260 . Therefore, neoadjuvant concurrent chemoradiation should be considered for treatment in @entity1 with locally advanced cervical @entity189 who could not undergo primary operation.
